Humira now licensed for psoriasis treatment in children

Humira (adalimumab) is now licensed for the treatment of severe chronic plaque psoriasis in children.

A child's arm displaying characteristic psoriatic plaques. | SCIENCE PHOTO LIBRARY
A child's arm displaying characteristic psoriatic plaques. | SCIENCE PHOTO LIBRARY

Humira can now be used in children from 4 years old with severe chronic plaque psoriasis who are inappropriate for, or have not responded sufficiently to topical therapies and phototherapies. The recommended dose is based on weight and administered subcutaneously weekly for the first two weeks then every other week. 

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more